2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 749

Childhood Takayasu Arteritis: Characteristics and Outcomes of a Mexican Cohort
Abstract Number: 750

Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort
Abstract Number: 751

Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group
Abstract Number: 752

Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis
Abstract Number: 753

Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis
Abstract Number: 754

Dynamic Distribution and Phenotype Shift from M1 to M2 of Macrophages in Vascular Lesions of Naïve and Treated Patients with Takayasu Arteritis
Abstract Number: 755

A Novel Diagnostic Algorithm for Polymyalgia Rheumatica Using Three Musculoskeletal Sites on Whole Body PET/CT
Abstract Number: 756

A Volar Pattern of 18F-Fluorodeoxyglucose Uptake at the Hand on Whole Body PET/CT Predicts Glucocorticoid-Responsive Disease in Polymyalgia Rheumatica
Abstract Number: 757

Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis
Abstract Number: 758

Interleukin-6 May Predict Disease Relapse During Long-term Follow-up in Takayasu’s Arteritis in a Han Chinese Population
Abstract Number: 759

Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica?
Abstract Number: 760

Prescribing Methotrexate in Polymyalgia Rheumatica: A Missed Opportunity?
Abstract Number: 761

Polymyalgia Rheumatica: Winter Is Coming
Abstract Number: 762

Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study
Abstract Number: 763

Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.